John Arthur , M.D., Ph.D. is the DCI Endowed Chair in Nephrology, a Professor of Medicine, and is the Director of the Southeastern Kidney Disease Consortium (SEKDC) and the Nephrology Proteomics Facility at the Medical University of South Carolina. He received his M.D. and Ph.D. degree from the University of Iowa. He received additional training in internal medicine and nephrology at Duke University. He has been on the MUSC faculty since 2001. He is the director of the Nephrology service and the director of dialysis at the Ralph H. Johnson VA Medical Center. He is the Director of the South Carolina Renal Disease Biomarkers SmartState Program (formerly the South Carolina Centers of Economic Excellence Program). As director of the Renal Disease Biomarkers program, he has developed the Special Lecture Series inviting Guest Lecturers around the nation to speak on relevant and innovative ideas in the field. His research program is funded by both the NIH and the VA and is focused upon biomarker discovery and qualification in renal diseases. He uses both targeted approaches and proteomic analysis to characterize novel biomarkers. The two major ongoing research projects are identifying biomarkers that predict prognosis in patients with acute kidney injury and patients with diabetic nephropathy. His clinical areas of expertise are acute kidney injury and acid-base and electrolyte abnormalities.
Southeastern Kidney Disease Consortium (SEKDC)
Dr. Arthur formed the Southeastern Kidney Disease Consortium (SEKDC) in 2012. Nephrologists, physicians, nurses and other health care representatives from across the United States attended the Inaugural Meeting held September 7-8, 2012 at The Francis Marion Hotel in Charleston, South Carolina. We invite nephrologists and other physicians interested in the treatment of patients with Kidney Disease to join the Consortium. SEKDC is dedicated to improving patient care, research, education, and communication among physicians who care for patients with kidney disease. The consortium is sponsored by the South Carolina Renal Disease Biomarkers SmartState Program.
Sponsored by the South Carolina Renal Disease Biomarkers SmartState Program and as a SEKDC initiative, Dr. Arthur was approved for the POSEIDON (Prevention, Optimizing Safety, Early Intervention and DetectiOn in Nephrology) Study on September 21, 2012. The specific aim of this study is to develop a data registry and sample bank for POSEIDON enrolled patients. Patients can consent to donating their residual kidney tissue if they undergo a kidney biopsy and blood or urine during routine clinical care procedures. There will be no expiration date for the length of time samples will be stored in the POSEIDON biobank. Samples collected in this study will aid future research that may include studies that would help identify better treatment and diagnostic options for patients with kidney disease. Also, in the future, the study may be expanded to include private clinics outside of MUSC for which an IRB amendment will be submitted by the Principal Investigator.
Curriculum Vitae and Publications
* Note in order to view this document
you will need to have the free Adobe
Reader® installed on your
*Available through the National
Library of Medicine's PubMed
Referrals and Appointments
|Patient Referral: Physicians please call MEDULINE at 1-800-922-5252.|